A Phase 2 interventional study of Nicotine replacement therapy - transdermal nicotine patch and Tailored behavioral intervention in Cigarette Smoking, sponsored by Iowa City Veterans Affairs Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-02.
Sponsored by Iowa City Veterans Affairs Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 371 studies in Cigarette Smoking with a site in United States — 68 open to participants now, 75 under way, 3 of them phase 3. Cigarette Smoking · United States.
Among the 371 studies in Cigarette Smoking with a site in United States, this one is the 217th largest by enrollment of the 340 interventional ones that give a count, is one of 15 that started in 2012, is one of 48 in phase 2, and was the 71st registered.
477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.
Browse Cigarette Smoking studies →68 of the 371 studies in Cigarette Smoking with a site in United States are open now. Recruiting first, the newest first:
Roswell Park Cancer Institute · Sites in United States
Ages 18–30
Virginia Polytechnic Institute and State University · Sites in United States
Ages 21+
University of California, Irvine · Sites in United States
Ages 50–80
VA Office of Research and Development · Sites in United States
Ages 21+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
371 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 56 · Phase 3 10 · Phase 4 22
First in 1997; this study’s year is marked. 15 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 96 across 407 interventional studies indexed under Cigarette Smoking.
Median enrollment 96 across the 340 interventional studies, 159 across the 30 observational. Of the 280 that completed or were terminated, 137 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 371 have an industry lead sponsor. The 10 most frequent:
Iowa City Veterans Affairs Medical Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Iowa City Veterans Affairs Medical Center has 1 study filed under Cigarette Smoking — fewer than ten, so there is no comparison to draw.
34 of the studies in Cigarette Smoking with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05008848Phase 3Alliance for Clinical Trials in OncologyReaching Rural Cancer Survivors Who Smoke Using Text-Based Program | 2027-04-23 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT05836103Johns Hopkins Bloomberg School of Public HealthTesting the Impact of Smartphone-based Messaging to Support Young Adult Smoking Cessation | 2026-11-30 |
| NCT05707871Wake Forest University Health SciencesCardiovascular Effects of Very Low Nicotine Content Cigarettes | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 371 studies in Cigarette Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed work is designed to help increase access to tobacco cessation services among rural veterans and to develop more effective treatment services that better address comorbid issues commonly experienced by rural smokers. The objectives are:
Tobacco use remains the leading preventable cause of morbidity and mortality in our society. Results from epidemiologic studies indicate that tobacco use is especially elevated among those living in rural areas. Although interventions exist that are both effective and cost-effective, few rural smokers utilize them during any given quit attempt. A lack of local treatment resources, the travel distance required to obtain treatment, and a reduced tendency to visit primary care on a regular basis all appear to contribute to the lower levels of treatment for nicotine dependence in rural smokers.
Smokers frequently experience conditions and concerns that adversely impact their ability to quit smoking. Depression and risky alcohol use, both of which are prevalent among smokers, reduce the likelihood of successfully quitting smoking. Concern about gaining weight, a common consequence of quitting smoking, is also frequently cited by smokers as an important barrier to quitting. Therefore, in order to be most effective, tobacco cessation interventions will need to address these important issues. Presently, treatment for nicotine dependence, risky alcohol use, depression, and weight management is typically delivered separately and without optimal integration among providers, an approach which only serves to fragment care and increase the number of required visits, further reduce rural smokers' access to care.
In an effort to address these barriers, the current study will evaluate a telephone intervention for tobacco use that also addresses issues related to risky alcohol use, depressed mood, and postcessation weight gain based on each individual smoker's needs. Results will provide valuable information regarding the potential to more widely implement an individually-tailored telephone intervention for rural smokers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
Drug: Nicotine replacement therapy - transdermal nicotine patch · Behavioral: Tailored behavioral intervention · Drug: Nicotine replacement therapy - nicotine gum · Drug: Nicotine replacement therapy - nicotine lozenge · Drug: Bupropion Sustained Release · Drug: Varenicline · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge · Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion · Behavioral: Alcohol use risk reduction · Behavioral: Behavioral activation for the treatment of depression · Behavioral: Behavioral management of post-cessation weight gain
Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
Drug: Nicotine replacement therapy - transdermal nicotine patch · Behavioral: Tobacco quit line referral · Drug: Nicotine replacement therapy - nicotine gum · Drug: Nicotine replacement therapy - nicotine lozenge · Drug: Bupropion Sustained Release · Drug: Varenicline · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge · Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion
Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Also known as: Zyban
Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Also known as: Chantix
Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
Also known as: Risky alcohol use, Harm reduction
Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
Also known as: Depression
Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
Also known as: Weight management
Treatment Satisfaction
Participants' impressions of and satisfaction with the intervention will be assessed by interview at the end of treatment.
Time frame: End of treatment (seven weeks after baseline)
Number of Participants Abstinent From Tobacco Use
At the six-month follow-up contact, participants will be questioned regarding self-reported tobacco use over the past seven days (point prevalence abstinence).
Time frame: Six-month follow-up
Alcohol Use
Alcohol use during the previous seven days will be assessed among those receiving the risky alcohol use treatment module and those in the quitline referral condition who would have been eligible for the intervention if assigned to the tailored treatment group.
Time frame: Six-month follow-up
Depressive Symptoms
Depressive symptoms as measured using the Patient Health Questionnaire 9 (PHQ-9). Possible scores range from 0 to 27, with higher scores indicating greater levels of depressive symptoms.
Time frame: Six-month follow-up
Body Weight
Self-reported body weight.
Time frame: Six-month follow-up
Enrollment Rate
The number of participants enrolled will be tracked as a measure of the feasibility of the intervention approached for the entire six-month recruitment period.
Time frame: 6 months after study initiation
Retention
The number of participants who remain in the study throughout the seven-week treatment period will be computed as an indicator of the feasibility of the treatment approach.
Time frame: End of treatment (seven weeks after baseline)
Treatment Attendance
The number of treatment calls completed (out of six total) will be calculated for all participants in the Tailored Intervention group as an indicator of the feasibility of the treatment approach.
Time frame: End of treatment (seven weeks after baseline)
| Milestone | Tailored Intervention Group | Enhanced Standard of Care Group |
|---|---|---|
| Started | 31 | 32 |
| Completed | 23 | 28 |
| Not completed | 8 | 4 |
| Withdrew: Lost to follow-up | 8 | 4 |
Participants' impressions of and satisfaction with the intervention will be assessed by interview at the end of treatment.
| Participants | Tailored Intervention Group | Enhanced Standard of Care Group |
|---|---|---|
| Found treatment very or extremely useful | 17 | 6 |
| Found medication to be very or extremely useful | 16 | 7 |
| Found treatment to be very or extremely convenient | 16 | 9 |
| Found treatment to be very or extremely difficult | 5 | 5 |
| Liked that treatment was delivered by phone | 21 | 10 |
At the six-month follow-up contact, participants will be questioned regarding self-reported tobacco use over the past seven days (point prevalence abstinence).
| Participants | Tailored Intervention Group | Enhanced Standard of Care Group |
|---|---|---|
| Number of Participants Abstinent From Tobacco Use | 9 | 9 |
Alcohol use during the previous seven days will be assessed among those receiving the risky alcohol use treatment module and those in the quitline referral condition who would have been eligible for the intervention if assigned to the tailored treatment group.
| Drinks consumed per day | Tailored Intervention Group | Enhanced Standard of Care Group |
|---|---|---|
| Alcohol Use | 9.5 ± 0.7 | 2.8 ± 3.2 |
Depressive symptoms as measured using the Patient Health Questionnaire 9 (PHQ-9). Possible scores range from 0 to 27, with higher scores indicating greater levels of depressive symptoms.
| units on a scale | Tailored Intervention Group | Enhanced Standard of Care Group |
|---|---|---|
| Depressive Symptoms | 7.0 ± 5.4 | 3.9 ± 2.7 |
Self-reported body weight.
| Pounds | Tailored Intervention Group | Enhanced Standard of Care Group |
|---|---|---|
| Body Weight | 214.0 ± 38.1 | 228.2 ± 45.5 |
The number of participants enrolled will be tracked as a measure of the feasibility of the intervention approached for the entire six-month recruitment period.
| Participants | Tailored Intervention Group | Enhanced Standard of Care Group |
|---|---|---|
| Enrollment Rate | 31 | 32 |
The number of participants who remain in the study throughout the seven-week treatment period will be computed as an indicator of the feasibility of the treatment approach.
| Participants | Tailored Intervention Group |
|---|---|
| Retention | 16 |
The number of treatment calls completed (out of six total) will be calculated for all participants in the Tailored Intervention group as an indicator of the feasibility of the treatment approach.
| Calls | Tailored Intervention Group |
|---|---|
| Treatment Attendance | 4.0 (0 to 6) |
Collected over Six months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tailored Intervention Group | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Enhanced Standard of Care Group | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| Age, Categorical(Participants) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 29 | 55 |
| >=65 years | 5 | 3 | 8 |
| Age, Continuous(years) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| Mean | 55.1 ± 11.5 | 58.5 ± 8.8 | 56.8 ± 10.3 |
| Sex: Female, Male(Participants) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| Female | 3 | 5 | 8 |
| Male | 28 | 27 | 55 |
| Region of Enrollment(Participants) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| United States | 31 | 32 | 63 |
| Nicotine dependence(units on a scale) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| Mean | 5.6 ± 2.3 | 5.7 ± 2.1 | 5.7 ± 2.2 |
| Cigarettes smoked per day(cigarettes/day) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| Mean | 22.3 ± 10.3 | 27.2 ± 25.7 | 24.7 ± 19.4 |
| Prior quit attempts lasting at least 24 hours(quit attempts) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| Mean | 6.6 ± 8.1 | 9.4 ± 19.6 | 8.0 ± 15.0 |
| Readiness to quit smoking(units on a scale) | Tailored Intervention Group | Enhanced Standard of Care Group | Total |
|---|---|---|---|
| Mean | 6.8 ± 1.1 | 6.5 ± 1.3 | 6.6 ± 1.2 |
1 further baseline measures are reported on the registry.
The record gives a start of Jun 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Iowa City Veterans Affairs Medical Center